Pivotal clinical trials (e.g., CheckMate-649 for nivolumab and KEYNOTE-811 for pembrolizumab) have demonstrated that ICIs targeting PD-1/PD-L1, particularly in combination with chemotherapy, significantly improve survival outcomes in advanced GC patients (3, 4). This evidence concerns the gene CD274 and gastric cancer.